SMSPHARMA

Date: 09th August, 2023 To, The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here herewith a copy of investor presentation of the Company for the first quarter ended 30th June, 2023. This Investor Presentation may also be accessed on the website of the Company at www.smspharma.com Kindly take the same on record and disseminate on your website. Thanking you Yours Faithfully For SMS Pharmaceuticals Limited Thirumalesh Tumma Company Secretary SMS Pharmaceuticals Limited Investor Presentation August 2023 1 1 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with anycontract orbinding commitment whatsoever.No offering of securities oftheCompany will be made exceptbymeansof a statutory offeringdocumentcontaining detailedinformationabouttheCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentationisexpresslyexcluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets,theperformanceoftheindustryinIndiaandworld-wide,competition,thecompany’sabilitytosuccessfullyimplementitsstrategy,theCompany’sfuturelevelsofgrowthand expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation.TheCompanyassumesnoobligationtoupdateanyforward-lookinginformationcontainedinthisPresentation.Anyforward-lookingstatementsandprojectionsmadeby thirdpartiesincludedinthisPresentationarenotadoptedbytheCompanyandtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections. 2 Table of Contents Company Overview ………………………………………………………………………….04-20 Key Strategic Focus…….…………………………………………..………………..……...21-27 Financial Highlights ……………………………………………………………………….…28-31 Historical Performance at a Glance ………………………………………………….32-36 3 Company at a Glance Genesis CRAMS Business  A30-yearsoldresearch-drivencompanyheadquarteredinHyderabad.  Engaged in providing quality alternative manufacturing destination to multinationals for theircontractresearchandmanufacturingneeds.  API focused company with 2 world class operating facilities in Hyderabad&Vizag,India.  InstalledCapacity:1951KL  Backward-integrated with low dependency on imports for raw  TopCustomers:Mylan,Laurus,Pharmathen&Lupin material  OtherDetails:HugemanufacturingfacilitytosupportvariousrangeofAPIs Integrated model Reach  80% of the intermediates are consumed by the API in-house  800+ Customers business.Lowimportdependency.  75+ Countries  JVwithSpanishpharmagiantChemoIbericaS.A.forR&D  40+ Products  Vertically integrated through VKT Pharmaceuticals Pvt. Ltd. -  80+ Regulatory Fillings An Associate company for semi-finished and finished  30+ Process Patents formulations Capacity Overview API Business  HyderabadPlant:  ~96%ofrevenueisderivedthroughAPIbusiness  InstalledCapacity:120KL  40+productsspreadacross14therapeuticsegments.  Products: Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan  Top therapeutic segments - Anti-Diabetic, Anti-Ulcer, Anti-Migraine, ARV, Anti- Succinate,Itraconazole,EletriptanHBr Epileptic,Anti-Inflammatory& Anti-ErectileDysfunction  VisakhapatnamPlant:  Global and Domestic leadership in key complex, specialized products like Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole ,  InstalledCapacity:3,000KL Eletriptan HBr, Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine,  Products: Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamotrigine,Efavirenz&Sitagliptin. Lamuvidine,Lamotrigine,Efavirenz&Sitagliptin.  Oneofthelargestsingle-block,single-productplantinAsia  Certifications:USFDA,EUGMP,KFDA,CDCSO&PMDA 5 Transformation Over the Years Diversification + Value-Addition + Expansion Awards & Recognitions Way Forward Got Listed Acquisition Won the prestigious Scaling Up Successfully developed & “Indian Pharma Bulk commercialized Covid-19 Acquired a facility to SMS got listed on drug company of the Became the largest treated APIs (Favipiravir & manufacture Niche the NSE, BSE (Indian year” award and manufacturer of Remdesivir) in FY2022. and High value stock exchange) – “Best bulk drug Ranitidine API in the FY2023: Commercialization products to have a Public Listed export company of world of Anti-Diabetic products diversified portfolio. company. the year” award and Ibuprofen from Govt. of India 1989 1995 1997 2000 2003 2007 2010 2015 2017 2021-2023 Recognition USFDA Audit Green Field Inception Demerger Project Faced our first Recognized USFDA audit SMS Pharma was by govt. of Started a green field Demerged SMS (successfully); SMS started with a single India with a project group into 2 Entities API was Part of a unit-product facility Jawaharlal Silver to build an API –SMS Para IV filing from an rolling trophy for the Pharmaceuticals, facility in more than MCN company. best productivity of SMS Lifesciences. 100 acres of Land. the year. 6 Highly Competent Team…To Drive the Future Growth Mr. Ramesh Babu Potluri Mr. P. Sarath Kumar Sri Sarvepalli Srinivas Sri Sravan Kudravalli Mr. Vamsi Krishna Potluri Chairman & MD Director Director Director Executive Director • Post-graduateTechnocrat. • Founder partner of the • Holds a B.Com. Degree from • Commerce Graduate from • Bachelor’s in Engineering in EEE • Started his career in the year Sarath&Associates. theUniversityofDelhi. Osmania University and a from BITS Pilani Dubai Campus. 1984 with Cheminor Drugs • Chartered Accountant with • Accomplished Business Fellow member of the And Masters in Engineering Limited(GroupofDr.Reddy’s about 26 years of standing in leader with 3+ decades of Institute of Chartered Management from Missouri Limited Laboratory), the Profession of Chartered provenleadershipexperience AccountantsofIndia. University of Science & Hyderabad. AccountancyandConsulting. in leading Public / Private • Partner in a reputed Technology-Rolla. • Played a key role in getting • Bachelor of Law and Sector enterprises with Chartered Accountancy firm • Joined Ohm Labs – the biggest US FDA approval for Certified Fraud Examiner & decisiveandforwardthinking and has experience in the manufacturing hub of Ranbaxy Ibuprofen Certified Forensic Accounting with a strong vision and area of Auditing, in US in the supply chain group • With his innovative skills and Professional. strategiccapability. Accountancy, Company Law and had hands on experience in methodological approaches • Advisor to C.I.D. of AP Police • 32+ years of experience in matter, Income Tax and managingthesupplychain. in R & D he developed cost and Central Bureau of leading Public / Private Finance. • Eldest son of Mr. Ramesh Babu effective Ibuprofen by using Investigation in investigation Sectors)-National Handloom • Involved in handling Internal Potluri,ChairmanandManaging cyanideroute. of major Economic Offence Development Corporation and Statutory Audits of Director, SMS Pharmaceuticals • Acquired SMS cases and is a Member of Ltd (NHDC) – Managing various Public and Private Ltd. Pharmaceuticals Limited in Multi Disciplinary Director -National Textile Companies and Systems 1990 and became the Investigationteam. Corporation Ltd (NTC) – designingforclients. Managing Director of the Chairman & Managing Company. Director. 7 State-of-the-art Manufacturing Facilities Particulars Hyderabad Visakhapatnam Year of Establishment 2000 2010 Plant Area: 19,685 Plant Area: 3,45,007 Area (units in Sq. M) Built Up: 5,127 Built Up: 39,704 Capacity 120KL 3,000 KL Famotidine, Rizatriptan Benzoate, Ibuprofen, Tenofavir, Ranolazine, Key Products Tadalafil, Sumatriptan Succinate, Levetiracetam, Lamuvidine, Itraconazole, EletriptanHBr etc. Lamotrigine, Efavirenz, Sitagliptin etc. Regulatory Approvals USFDA,EUGMP, KFDA,CDSCO,PMDA USFDA,KFDA,CDSCO,PMDA • 3 times approved by USFDA. • 5 times approved by USFDA. • Flagship, Multipurpose API • Facility aligned for manufacturing facility. manufacturing niche small • Facility aligned for manufacturing Key Features volume molecules. niche large-volume molecules. • One of the largest exporter of • Huge CMO facility to cater highly Triptans reputed clients • Dedicated Ibuprofen largest single -block, single product plant in Asia Disclaimer:Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness 8 Strong Thrust on R&D Product Development 01 Added 20 new products to the company’s product basket over the past few years. Technical Team 02 Comprises 100+ scientists & 8 PHDs; 45 scientists ensure disciplined adherence to regulatory standards and client specifications Quality Management 03 Optimized many Anti-Ulcer APIs to position the company as a leader in the respective therapeutic area. Research & Development: Backbone Equipped Technology of APIs 04 Equipped with cutting edge technology & sophisticated equipment that has the capability to support the entire R&D life cycle DMFs & Patents 05 Over 80+ DMFs filed; over 30 process patents filed Scaling Up 06 Product scale-up infrastructure comprises a kilo lab and a pilot plant. Pilot Plant is well equipped for DMF Filling. Kilo lab has a total capacity of scale up systems –4,500 Ltrs Innovation Developed an innovative path to recycle methyl mercaptan gas into useful solvent DMSO in 07 Ranitidine with a goal of environment protection; received the Indo-US GCNC award for this successfulachievement 9 Self-reliant Manufacturing Plants Particulars No. Total No. of Reactors 50 Minimum Size 50 L Maximum Size 3,000 L Total Capacity 57 KL Glass Lined Reactors 17 SS Reactors 31 Hydro-generators 2 Distillation Still 1 Glass Flasks 5  Pre-treatment plant capacity (MGF & Softner) 1750 Lts/ Hr. SS Centrifuges 18  DM Water generation by RO & EDI - 1000 Lts / Hr.  DM Water Storage capacity – 5000 Lts Rubber Lined Centrifuges 1  Power Generation by DG set 640 KV & 320 KV. Boilers 2Tons/Hr. & 3 Tons/Hr. Dryers 16  Vacuum Pumps, Steam & Water jet ejectors & Nitrogen Plant 20 NM3/ Hr. 10 …and a Wide Array of Manufacturing Capabilities Capacity Equipment Name MOC (Min-Max) Stainless steel Reactors SS 50 L – 32 KL Glass lined Reactors MS-GL 63 L – 10 KL Leaf Filters SS 80 – 100 L Nutsch Filters SS 80 – 1500 L Agitated Nutsche Filter Drier SS 2500 – 15000 L Sparkler Filter SS 10-177 L Centrifuges SS 24" - 60" Rotary Cone Vacuum Drier SS & MS GL 200 L – 3000 L Vacuum Tray Drier / Tray drier SS 12 – 96 Trays De-lumper SS 1000 – 2000 Kg/Hr Fluid Bed Drier SS 300 – 500 Kg Co-Mill SS 500 – 750 Kg/Hr Multi Mill SS 50-300 Kg/Hr Poly Gonal Blender SS 150 L – 3 KL Micronizer SS 20 – 200 Kg/Hr Micro Pulverizer SS 50-250 Kg/Hr Sifter SS 100-500 Kg/Hr Roller Compactor SS 400 Kg/Hr Note:SS –Stainless Steel , MS GL –Mild Steel Glass Lined 11 Supported by Comprehensive Chemicals and Process Capabilities… Distillation (Normal & Vaccum) Distillation (Normal & Vaccum) Condensation Oxidation Oxidations & Reductions Cyclisation n n o Fridel Craft Mesylation o i t i t a Methylation Reduction Condensation a r d Silyation r t y Electrophillic aromatic substitutions i h N Epoxidation e n Bromination D o Ketone Reductions n i t s o n Salt Formations a n i s y i t a Salt Formation o i i r o l o Coupling Reaction l y Grignard Reaction t a l h r d c A l y Hydro-Carbon Reactions C y k H Hydrogenation l A Alkylation Suzuki Coupling Reactions Acid Chloride reaction Dechlorination  Minimum temperature as -105°C and maximum temperature as 170°C in the reactor while manufacturing of various products in our manufacturing plant.  Capable to handle the above-mentioned reactions for various Active pharmaceutical ingredients of different therapeutic categories to human consumption manufactured on site. 12 12 …Resulting into Long Lasting Relationships with Marquee Clients 13 CSR Activities  Society Service  Educational Infrastructure  Empowering Differently Abled Children 15 CSR Activities  Sponsored & Constructed Z.P. High School at Poosapatriga Village, Andhra Pradesh  Sponsored for Borewell drilling  Donation of Oxygen cylinders at Kopperla Chinthapalli Village, Andhra Pradesh Village in aid of Covid 19 victims 16 CSR Activities  Sponsored & Constructed R.O water plant at Thammayapalem  We also Donated INR 20 Lakh to the police Viliage, Andhra Pradesh force to support their selfless service during covid times.  Extended financial support to Campus challenge 17 CSR Activities  Sponsored & Constructed: AP Balayogi Gurukulam, Kopperala, Vizinagaram, Andhra Pradesh 18 CSR Activities  Sponsored & Constructed MPUP School, Ayyanapet, Vizianagaram, Andhra Pradesh 19 Awards/Accolades Bulk Drug Company Indo US NCGC Award of the Year  First Indian pharma company to  India Pharma Bulk Drug Export Company of the Year Award from Government of India. receive Indo-US GCNC award for adopting green chemistry practices Pandit Jawaharlal Nehru  Received the Indian Pharma Bulk Drug Company Silver Rolling Trophy of the Year Award  Awarded Pandit Jawaharlal Nehru Silver Rolling Trophy for the best productivity effort in Andhra Pradesh 20 Key Strategic Focus Niche Product Portfolio Carved out a strong presence in complex, niche API therapies with a globalleadershipinmultipleproducts Expansion Brownfield capex of Rs. 200 crores in FY21 to augment the next leg of growth Unique Value Proposition Global presence, Strong domain expertise, cost leadership, long- standing relationships, Economies of scale Diversification Portfolio of 40+ products across 14 therapies catering 75+ countries in regulatedandsemi-regulatedmarkets De-risked and Integrated Value Chain Backward and Vertical Integration provides cost synergies and growth opportunities. Strategic focuson backward integration and intermediates has reduced supply chain and forex risks significantly.(~10%-15%oftheimportsfromChina) 22 Niche Product Portfolio Leadership in Select High-Value, Complex APIs API portfolio comprises of specialized and profitable products Growing share of High Value Products in niche therapeutic areas. Reflects the strong ability to foray intootherhigh-value,nicheandcomplexproducts By Value (%) Currently developing multiple products every year across 14 7% 3% 4% therapeutic areas, which include High Value as well as High 15% 1% VolumeProducts 17% 38% SMS Pharma has demonstrated an ability in the past to foray into new complex, profitable products and currently enjoys leadershippositioninmultipleAPImolecules. 14% ARV Anti-Ulcer Anti-Epileptic Anti-Aginal Anti-Migraine Anti-Inflammatory Anti-Diabetic Other The company has presence in multiple margin-lucrative, non- 1% By Volume (%) commoditized therapeutic areas like ARV, Anti-Epileptic, Anti- 1% Migraine,Anti-Anginal,etc. 4% 42% 1% The companyhas an expertise in synthesis and R&D which can 1% beleveragedtoforayintocomplexAPIproductsandtherapies 49% The company enjoys global leadership position across 10+ 2% productsacrosstherapies. ARV Anti-Ulcer Anti-Epileptic Anti-Aginal Anti-Migraine Anti-inflammatory Anti-Diabetic Other 23 Note:As of FY22 Expansion With ~ Rs. 200 crores capex at Vishakhapatnam Facility in FY21, the company is fully geared up for the next level of growth. • The brownfield capex is aimed towards capacity augmentation of multiple products and therapies. • The incremental capacity addition through the capex is 1,300 KL, predominantly aimed towards Ibuprofen capacity expansion. • With this capex, company is expected to be one of the largest Ibuprofen manufacturers globally. • The company is also leveraging long-standing relationships, domain expertise and strong R&D knowledge to foray into new therapies, products and geographies • Majority of the capex is funded through internal accruals and minimal debt, thus maintaining the robust Balance Sheet position. • Higher margins and profitability ratios expected through operating leverage and incremental revenue. 24 Unique Value Proposition Global Presence ~83% Exports Revenue (including deemed exports) in 75+ countries across 5 continents – Lower dependency on single country/region Long-standing Relationships Long standing relationships with suppliers and customers - Cost-efficient, consistent, sustainable raw material Strong Domain Expertise supplyandrevenue Promoters and Senior Management with a strong business pedigree and domain expertise in APIs and Intermediates – Alignment of interest of all internal Economies of Scale stakeholders Leadership position in key products, coupled with backward integration provides economies of scale – Lower Cost Leadership CompetitiveIntensity&HigherMargins From procurement to production till sales have a strong foundation and sound setup. Backward integration ensures cost- efficient manufacturing – Higher Profitability 25 Diversification Well-diversified across Geographies, Markets, Therapies, Products and Customers = Risk Reduction and Multiple Growth Avenues 01 02 03 04 Geography Markets API Therapies Customers • Regulated Markets contributed • Top 5 therapies contributed • Domestic: Largest client • Domestic -Export mix at ~76% of sales in FY23, with ~84%of sales in FY23 contributes ~10%of 17%:83%for FY23 Spain being the highest at~34% domestic sales whereas • Anti Diabetic products top 10 clients contribute • Presence across 75+ • Semi-Regulated Markets contributed highest at 38% to ~66% in FY23. countries contributed ~7% of sales in sales in FY23 FY23, with Africa being the • Exports: Largest client • None of the region highest at ~3% • Top 10 products contributed to contributes ~39% of contributes more than 84% to sales in FY23 exports sales whereas top 2/3rd of the revenue, with • Domestic Markets contributed 10 clients contribute ~66% Europecontributing the ~17%of sales in FY23, with • Leaders in Domestic market in in FY23. highest at ~47% of total Lupin being the highest at ~10%. most of top 10 products sales 26 De-risked & Integrated Value Chain Backward Integration Verticle Integration Strategic  Vertically integrated through VKT  Over the years, SMS Pharma has Pharmaceuticals Pvt.Ltd. -An Associate Investments strategically invested in backward company integration to be self-reliant and reduce across the Value • VKT Pharma Private Limited is engaged in supply chain risk. manufacture of formulations & semi- Chain • 80% of the intermediates are finishedformulationsviz.pellets. consumed by the API in-house • Company holds 36.55% as on 31st March business. 2023 in VKT Pharma and balance is held • Low dependency on China for raw by promoters which give the entire material sourcing (~10% of the controlinthemanufacturingcycle. raw material sourced from China) • VKTPharmagivesanedgebysavingcosts & eliminating imports with respect to formulations. • VKT has 6 approved ANDA’s out of which 4receivedinJanuary2022. 27 Consolidated Revenue Break-up – Quarterly QQQ111FFFYYY222113 Q4FY23 QQ11FFYY2224 e s i w 99% 98% 98% - t n e m 1% 2% 2% g e S API Intermediates & Others API Intermediates & Others API Intermediates & Others Q1FY23 Q4FY23 Q1FY24 e s i w 82% 85% 85% - y h p a r g o e G 18% 15% 15% Domestic Exports Domestic Exports Domestic Exports 29 API Therapy-wise Revenue Break-up – Quarterly QQQ111FFFYYY222113 Q4FY23 QQ11FFYY2224 5% 10% 26% 24% 3% 29% 27% 26% 29% 3% 19% 0% 2% 21% 10% 13% 11% 4% 16% 8% 13% ARV Anti-Ulcer ARV Anti-Ulcer ARV Anti-Ulcer Anti-Erectile dysfunction Anti-Migraine Anti-Erectile dysfunction Anti-Migraine Anti-Erectile Dysfunction Anti-Migraine Anti-Epileptic Anti-Diabetic Anti-Epileptic Anti-Diabetic Anti Eplipetic Anti-Diabetic Others Others Others 30 Consolidated Profit & Loss Statement Particulars (Rs. crores) Q1FY24 Q1FY23 YoY% Q4FY23 QoQ% Net Revenue from Operations (Net of Excise) 135.3 64.4 110% 149.4 -9% COGS 87.9 47.8 102.2 Gross Profit 47.5 16.6 185% 47.3 0% Gross Margin (%) 35.1% 25.8% 924bps 31.6% 344bps Employee Expenses 13.6 11.5 14.4 Other Expenses 7.7 5.9 9.7 EBITDA 26.2 -0.8 NA 23.2 12.7% EBITDA Margin (%) 19.4% -1.2% NA 15.5% 380bps Other Income 0.5 0.8 1.3 Finance Costs 6.3 4.9 5.9 Depreciation 7.7 7.9 8.0 PBT 12.7 -12.8 NA 10.6 19% Taxes 3.9 -2.6 2.6 Reported PAT 8.8 -10.2 NA 8.1 9% Add: Share of Associzte Profit/Loss 0.5 -2.6 -1.9 PAT after MI & Assoc 9.4 -12.7 NA 6.2 51% PAT Margin (%) 6.5% -15.8% NA 5.4% 112bps Earnings Per Share (EPS) 1.10 -1.51 NA 0.73 51% 31 Historical Financial Performance Consolidated Revenue (Rs. Crores) EBITDA (Rs. Crores) PAT (Rs. Crores) 125 63 62 120 563 520 522 93 463 465 90 40 412 80 32 32 55 -7 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 EBITDA Margin (%) Net Worth (In Crores) Leverage (X) 22.1% 23.0% 470 461 0.58 20.2% 428 19.4% 19.4% 0.48 348 0.42 0.41 322 285 10.4% 0.25 0.22 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 33 Consolidated Profit & Loss Statement Particulars (Rs. crores) FY23 FY22 FY21 FY20 FY19 FY18 Revenuefrom Operations 522.1 519.9 563.2 411.9 464.9 464.9 COGS 389.5 330.5 379.4 280.0 327.6 326.6 Gross Profit 132.6 189.4 183.8 131.9 137.4 138.3 Gross Profit Margin 25.4% 36.4% 32.6% 32.0% 29.5% 29.7% Employee Cost 50.1 51.0 41.2 39.4 35.6 32.8 Other Expenses 28.0 24.0 21.5 12.7 11.7 12.1 EBITDA 54.5 114.3 121.1 79.9 90.1 93.3 EBITDA Margin 10.4% 22.0% 21.5% 19.4% 19.4% 20.1% Other Income 4.9 5.2 3.5 5.1 3.4 2.4 Depreciation 32.1 32.2 22.3 22.1 19.3 19.9 EBIT 27.3 87.4 102.3 63.0 74.2 75.8 EBIT Margin 5.2% 16.8% 18.2% 15.3% 16.0% 16.3% Finance Cost 21.9 18.9 11.2 12.2 11.9 15.5 Profit from Associates -10.9 -5.7 1.6 -1.1 -1.4 -8.7 Exceptional Item (Gain) / Loss 0.0 0.0 0.0 0.0 0.0 0.0 Profit before Tax -5.6 62.8 92.7 49.6 60.9 51.6 PBT Margin N.A. 12.1% 16.5% 12.1% 13.1% 11.1% Tax 1.5 0.6 30.2 18.1 20.9 19.9 PAT -7.1 62.2 62.5 31.6 40.0 31.7 PAT Margin % N.A. 12.0% 11.1% 7.7% 8.6% 6.8% EPS (in Rs.) -0.2 7.35 7.39 3.73 4.73 3.75 34 Consolidated Balance Sheet Equities & Liabilities (Rs. crores) FY23 FY22 FY21 FY20 FY19 FY18 Assets (Rs. crores) FY23 FY22 FY21 FY20 FY19 FY18 Equity Non Current assets Equity Share capital 8.5 8.5 8.5 8.5 8.5 8.5 Property, Plant and Equipment 409.5 434.1 452.3 275.2 280.1 278.9 Other Equity 452.1 485.3 419.7 339.8 313.5 276.0 Capital work in progress 33.2 11.0 6.7 42.1 18.3 8.2 Non Controlling Interest 0.0 0.0 0.0 0.0 0.0 0.0 Intangible assets 1.5 1.4 1.6 0.8 1.1 0.4 Total Equity 460.5 493.8 428.2 348.2 321.9 284.5 Right to use assets 1.1 2.6 3.6 4.5 0.0 0.0 Financial liabilities Financial Assets 0.0 0.0 0.0 0.0 0.0 0.0 (i) Borrowings 149.5 147.4 68.2 62.2 71.4 121.1 (i) Investments 10.5 45.0 45.0 25.8 27.0 28.4 (ii) Other Financial liabilities 2.1 3.2 4.8 0.0 0.0 0.6 (ii) Other Financial Assets 7.6 7.6 5.8 5.6 5.6 4.4 Other non current Liability 0.0 0.0 0.0 0.0 0.0 0.0 Deferred Tax Assets (net) 0.0 0.0 0.0 0.0 0.0 0.0 Deferred tax liabilities (Net) 39.6 53.9 39.7 30.6 23.0 41.0 Other non-current assets 5.6 4.3 5.6 35.1 19.1 13.8 Provisions 1.8 1.8 1.7 1.5 2.2 1.4 Total Non Current Assets 469.0 505.9 502.9 389.1 351.2 334.0 Total Non Current Liabilities 164.2 192.9 206.3 114.5 94.3 96.6 Current Assets Financial liabilities Inventories 223.5 251.1 137.8 129.2 136.4 107.5 (i) Borrowings 110.6 103.1 61.2 70.8 58.4 131.4 Financial Assets 0.0 0.0 0.0 0.0 0.0 0.0 (ii) Lease Liabilities 1.0 0.9 0.0 0.0 0.0 0.9 Investments 0.0 0.0 0.0 0.0 0.0 0.0 (iii) Trade Payables 72.9 65.4 44.5 47.7 38.7 113.2 (i) Trade receivables 148.4 48.5 105.7 48.8 26.0 24.1 (iii) Other financial liabilities 6.8 17.0 28.4 13.0 17.5 5.5 (ii) Cash and Bank Balances 7.4 46.5 40.4 9.5 14.8 12.6 Provisions 1.0 0.8 0.8 0.7 0.7 0.7 (iii) Bank Balances & Financial 6.7 0.4 0.4 0.4 0.3 0.6 Other current liabilities 4.2 8.2 10.4 10.4 5.9 Assets 2.9 Current Tax Assets(Net) 5.8 4.5 3.0 3.1 0.4 0.0 Current tax liabilities (Net) 0.0 0.0 0.0 0.0 0.0 0.0 Other current assets 19.0 26.1 22.0 27.8 29.6 23.6 Total Current Liabilities 254.9 196.3 195.4 145.2 142.5 121.5 Total Current Assets 410.7 377.1 309.3 218.8 207.6 168.5 Non current Asset held for sale 0.0 0.0 0 0.0 0.0 Total Equity and Liabilities 879.6 883.0 829.9 607.9 558.8 502.5 Total Assets 879.6 883.0 812.2 607.9 558.8 502.5 35 Consolidated Cashflow Statement Particulars (Rs. crores) FY23 FY22 FY21 FY20 FY19 FY18 Net Profit before Tax and Extraordinary items 5.4 68.5 91.1 50.8 62.4 60.3 Adjustments for: Non Cash Items / Other Investment 53.0 49.9 27.8 28.7 26.8 31.1 or Financial Items Operating profit before working capital changes 58.3 118.4 118.9 79.4 89.2 91.4 Changes in working capital -31.3 -58.4 -12.4 -27.6 -26.0 -48.5 Cash generated from Operations 27.1 60.0 106.5 51.8 63.1 43.0 Direct taxes paid (net of refund) -4.6 -14.9 16.0 12.1 13.4 11.1 Net Cash from Operating Activities 22.5 45.1 90.5 39.7 49.8 31.8 Net Cash from Investing Activities -29.7 -27.2 -151.6 -42.6 -34.7 -16.6 Net Cash from Financing Activities -32.0 -11.8 92.0 -2.4 -12.9 -14.9 Net Decrease in Cash and Cash equivalents -39.2 6.2 30.9 -5.3 2.2 0.3 Add: Cash & Cash equivalents at the beginning of 46.6 40.4 9.5 14.8 12.6 12.3 the period Cash & Cash equivalents at the end of the period 7.4 46.6 40.4 9.5 14.8 12.6 36 For further information, please contact Company: Investor Relations Advisor: CIN: L24239TG1987PLC008066 CIN: U74140MH2010PTC204285 Mr. Thirumalesh Tumma Mr. Jigar Kavaiya / Mr. Parin Narichania Email: complianceofficer@smspharma.com E: jigar.kavaiya@sgapl.net / parin.n@sgapl.net Contact no.: +91 9100123244 T: +91 9920602034 / +91 9930025733 www.smspharma.com www.sgapl.net 37 37